All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the updates from the NCRI AML18 and AML19 clinical trials?

During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, the AML Hub was pleased to speak to Nigel Russell, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the updates from the NCRI AML18 and AML19 clinical trials?

What are the updates from the NCRI AML18 and AML19 clinical trials?

Russell begins by discussing results from the AML19 clinical trial, where younger adult patients with acute myeloid leukemia or high-risk myelodysplastic syndromes were treated with either a single or fractionated dose of gemtuzumab ozogamicin paired with either daunorubicin-cytarabine or FLAG-Ida chemotherapy regimens followed by consolidation treatment with high-dose cytarabine. Russell considers survival and minimal residue disease negativity rates, outcomes in mutational subgroups, and the use of CPX-351 in specific patient populations.

Russell then goes on to highlight findings from the AML18 clinical trial, in which elderly patients without adverse-risk cytogenetics disease were treated with daunorubicin-cytarabine chemotherapy with or without single or fractionated dose gemtuzumab ozogamicin. Finally, Russell discusses the differences in survival rates and minimal residue disease negativity in those who received a stem cell transplant and the implications of these results on the choice of induction chemotherapy in this patient population.


Subscribe to get the best content related to AML delivered to your inbox